Navigation Links
Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
Date:2/12/2009

EMERYVILLE, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced financial results for the three-month and six-month periods ended December 31, 2008.

Revenues for the second quarter of fiscal 2009 were $3.5 million compared to $3.7 million for the second quarter of fiscal 2008. Research and development expenses were $10.4 million for the three months ended December 31, 2008 compared to $7.4 million for the three months ended December 31, 2007. General and administrative expenses were $1.2 million for the three months ended December 31, 2008 compared to $1.9 million for the three months ended December 31, 2007.

The net loss for the second quarter of fiscal 2009 was $7.8 million, or $0.29 per share, compared to a net loss of $6.9 million, or $0.36 per share, for the second quarter of fiscal 2008.

Revenues for the first six months of fiscal 2009 were $7.1 million compared to revenues of $7.6 million for the same period of fiscal 2008. Research and development expenses were $15.8 million for the six months ended December 31, 2008 compared to $12.9 million for the six months ended December 31, 2007. General and administrative expenses were $2.5 million for the six months ended December 31, 2008 compared to $3.6 million for the six months ended December 31, 2007. The net loss for the six months ended December 31, 2008 was $10.6 million, or $0.39 per share, compared to a net loss of $7.8 million, or $0.65 per share, for the six-months ended December 31, 2007.

Cash, cash equivalents and investments were $32.2 million at December 31, 2008. The cash and total investments balance included cash and equivalents of $6.9 million, short term investments of $16.4 million and auction-rate securities carried at an estimated fair value of $8.9 million
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
2. Neurobiological Technologies Announces Suspension of Viprinex Development
3. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
4. Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
5. Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10
6. Neurobiological Technologies Sets Date for First Quarter Financial Results
7. Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
8. Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
9. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
10. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
11. Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  Now available is a stem cell ... Regenerative Therapies , located in Guadalajara, Mexico ... people a new health option: stem cell therapies ... countless patients suffer from joint and muscle injuries due ... tears, torn rotator cuff, tennis elbow, and knee injuries. ...
(Date:7/24/2014)... by group leader Yung-Eun Sung has announced that ... and nitrogen-doped graphenes which can be applied as ... cells. Yung-Eun Sung is both a group leader ... for Basic Science* (IBS) and a professor at ... great significance with regards to the development of ...
(Date:7/24/2014)... , July 24, 2014 Research and ... "Global Cell Culture Market 2014-2018" report to their ... Cell culture is the in vitro growth of ... research, cell studies, and biopharmaceutical production. Cell culture is ... Cell culture instruments and cell culture consumables are necessary ...
(Date:7/24/2014)... N.J. , July 24, 2014  CorMedix ... on developing and commercializing therapeutic products for the ... today announces receipt of notice on July 18, ... the NYSE-MKT has accepted the CorMedix plan to ... NYSE-MKT. As a result, the NYSE-MKT is continuing ...
Breaking Biology Technology:Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3
... BIRMINGHAM, Ala., Oct. 31 BioCryst,Pharmaceuticals, Inc. (Nasdaq: ... quarter ended September 30, 2008., Third Quarter ... ended September 30, 2008, the Company reported,collaborative and ... to $20.5 million for the three months ended ...
... and waves erode billions of tons of soil from ... plagued with excessive amounts of suspended sediment. According to ... the largest nonpoint source pollution in the environment. , ... obvious wind, water and wave forces breaking apart particles ...
... 30 AVAX Technologies, Inc.,(OTC Bulletin Board: AVXT) ... it closed a bridge loan financing pursuant to ... by the Amendment to Convertible,Note and Warrant Purchase ... Company sold convertible promissory notes,(the "Notes") in the ...
Cached Biology Technology:BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 2BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 3BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 4BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 5BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 6BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 7BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 8BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 9Virginia Tech engineers identify conditions that initiate erosion 2Virginia Tech engineers identify conditions that initiate erosion 3AVAX Technologies, Inc. Announces Closing of Bridge Loan Financing 2
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... of native animal species for food or commercial food ... factor in the decline of many species of primates ... that more than half of the species being consumed ... "By surveying not only the meat made available for ... the forest by hunters and brought to villages for ...
(Date:7/24/2014)... study has identified two factors that characterize sustainable ... production of highly qualified physics teachers. Specifically, one ... physics teacher education in combination with institutional motivation ... viable. Science, Technology, Engineering and Math (STEM) teacher ... study points the way for institutions seeking to ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4Creating sustainable STEM teacher preparation programs 2
... drug for cocaine addiction and overdose, Journal of the ... what they term the most powerful substance ever discovered for ... to the world,s first effective medicine for fighting overdoses and ... the Sept. 24 issue of the Journal of the ...
... A researcher at Oregon State University has used ... to identify counties in Oregon with high numbers of ... in fighting the illegal drug. The study, presented ... from four sources then identified five counties with the ...
... a muscle fiber mesh at the neuromuscular junction. New work ... Cell Biology reveals that an extracellular matrix protein called ... fit together type="rel"doi="10.1083/jcb.2008. , A neuromuscular junction, or synapse, in ... nerve terminal meeting a flat, oval structure on the muscle ...
Cached Biology News:American Chemical Society's Weekly PressPac -- Sept. 10, 2008 2American Chemical Society's Weekly PressPac -- Sept. 10, 2008 3American Chemical Society's Weekly PressPac -- Sept. 10, 2008 4American Chemical Society's Weekly PressPac -- Sept. 10, 2008 5American Chemical Society's Weekly PressPac -- Sept. 10, 2008 6American Chemical Society's Weekly PressPac -- Sept. 10, 2008 7American Chemical Society's Weekly PressPac -- Sept. 10, 2008 8New method identifies meth hot spots 2New method identifies meth hot spots 3
...
Request Info...
Streptomycin sulfate an aminoglycoside used for bacterial selection binds to the small ribosomal subunit and interferes with protein biosynthesis.21H39N7O12)2x3H2SO4Formula weight:...
Adducin beta (C-16)...
Biology Products: